/CRVS
CRVS Stock - Corvus Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$7.49-1.96%
$0.15 (-1.96%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.66
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+93.6%upside
Target: $14.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRVS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.42 – $7.56
TARGET (TP)$14.50
STOP LOSS$6.89
RISK/REWARD1:11.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.63
52W High$9.60
52W Low$2.54
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-27,548,000 | $-23,407,000 | $-32,565,000 | $-38,630,000 | $-43,760,000 |
| Net Income | $-62,293,000 | $-27,029,000 | $-41,307,000 | $-43,241,000 | $-5,995,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.02 | $-0.56 | $-0.89 | $-1.03 | $-0.20 |
Company Overview
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 51.3% Upside
Now
$7
Low
$11
Average
$16
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 13th 2025 | Barclays | Initiation | Overweight | $16 |
| January 2nd 2025 | H.C. Wainwright | Initiation | Buy | $11 |
| August 18th 2023 | Oppenheimer | Initiation | Outperform | $7 |
Earnings History & Surprises
CRVSBeat Rate
37%
Last 19 quarters
Avg Surprise
-12.5%
EPS vs Estimate
Beats / Misses
7/6
6 met exactly
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.14vs$-0.14
Q2 24
0.0%
$-0.12vs$-0.12
Q3 24
+41.7%
$-0.07vs$-0.12
Q4 24
0.0%
$-0.11vs$-0.11
Q1 25
-50.0%
$-0.18vs$-0.12
Q2 25
0.0%
$-0.13vs$-0.13
Q3 25
+23.1%
$-0.10vs$-0.13
Q4 25
+14.3%
$-0.12vs$-0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.14 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.14 | $-0.12 | +14.3% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.13 | $-0.10 | +23.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.13 | $-0.13 | 0.0% | = MET |
Q1 2025 | Mar 25, 2025 | $-0.12 | $-0.18 | -50.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.11 | $-0.11 | 0.0% | = MET |
Q3 2024 | Aug 6, 2024 | $-0.12 | $-0.07 | +41.7% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.12 | $-0.12 | 0.0% | = MET |
Q1 2024 | Mar 19, 2024 | $-0.14 | $-0.14 | 0.0% | = MET |
Q4 2023 | Nov 7, 2023 | $-0.16 | $-0.12 | +25.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.14 | $-0.14 | 0.0% | = MET |
Q2 2023 | May 8, 2023 | $-0.16 | $-0.17 | -6.3% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $0.23 | $-0.21 | -191.3% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.16 | $-0.32 | -100.0% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.14 | $-0.18 | -28.6% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.20 | $-0.20 | 0.0% | = MET |
Q4 2021 | Nov 1, 2021 | $-0.30 | $-0.24 | +20.0% | ✓ BEAT |
Q3 2021 | Aug 2, 2021 | $-0.32 | $-0.28 | +12.5% | ✓ BEAT |
Q2 2021 | Apr 29, 2021 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Latest News
CDT Equity Sells Conduit Pharmaceuticals To Corvus Capital, CEO's Subsidiary, For $7M Via Stock And Pre-Funded Warrants
➖ NeutralBenzinga•Dec 12, 2025, 09:31 PM•Also:
Corvus Pharmaceuticals' Soquelitinib Shows Median Progression Free Survival Of 6.2 Months And Median Overall Survival Of 28.1 Months In T-Cell Lymphoma; Supports Ongoing Phase 3 Trial
📈 PositiveBenzinga•Dec 8, 2025, 03:32 PM
Corvus Pharma Q3 EPS $(0.12) Beats $(0.14) Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:01 PM
Corvus Pharmaceuticals To Present Final Phase 1 Data On Soquelitinib For R/R T Cell Lymphoma At ASH 2025
➖ NeutralBenzinga•Nov 3, 2025, 02:14 PM
Corvus Pharmaceuticals Presents Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer At The ESMO Congress 2025; Interim Data Shows Triplet Therapy With Ciforadenant, Ipilimumab And Nivolumab Is Feasible And Well Tolerated; Longer Follow-Up With Patients Still On Therapy Needed To Determine Potential Benefit Of Blocking Adenosine Signaling
📈 PositiveBenzinga•Oct 17, 2025, 02:03 PM
Barclays Initiates Coverage On Corvus Pharma with Overweight Rating, Announces Price Target of $16
📈 PositiveBenzinga•Oct 13, 2025, 12:04 PM•Also:
Frequently Asked Questions about CRVS
What is CRVS's current stock price?
Corvus Pharmaceuticals, Inc. (CRVS) is currently trading at $7.49 per share. The stock has moved -1.96% today.
What is the analyst price target for CRVS?
The average analyst price target for CRVS is $14.50, based on 1 analyst.
What sector is Corvus Pharmaceuticals, Inc. in?
Corvus Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CRVS's market cap?
Corvus Pharmaceuticals, Inc. has a market capitalization of $0.56 billion, making it a small-cap company.
Does CRVS pay dividends?
No, Corvus Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
AKBA
Akebia Therapeutics, Inc.
$1.66
Mkt Cap: $0.4B
CMPX
Compass Therapeutics, Inc.
$4.99
Mkt Cap: $0.7B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to CRVS for comparison